"PSA Rising for 18 Months. A 3.1 cm Lesion on MRI. Gleason 4+3 on Biopsy. He Was 62. He Taught for a Living. He Was Not Ready to Trade His Quality of Life for His Cancer Treatment."
Mr. Zhang had spent his career in front of people.
A 62-year-old associate professor, he had given three decades to his students - standing at the lectern, commanding a seminar room, projecting the authority and physical presence that teaching demands. He was precise, disciplined, and deeply aware of what his body communicated to the people around him. Urinary control was not an abstract concern for him. It was a professional requirement.
The PSA had been rising for eighteen months - from 4.2 to 11.8 ng/mL, a trajectory that his physician had been watching with increasing concern. The free-to-total PSA ratio was 0.12. The multiparametric MRI showed a PI-RADS 5 lesion: a 3.1 cm nodule in the right peripheral zone with capsular contact length above 1.5 cm and suspected extracapsular extension. The targeted fusion biopsy confirmed the diagnosis: Gleason 4+3=7, Grade Group 3 in six of twelve right-sided cores (cancer occupying 45%), and Gleason 3+3=6 in two left-sided cores. PSMA PET/CT showed no pelvic lymph node or bone metastases. Clinical stage: cT2cN0M0 - intermediate-high risk localized prostate cancer.
The multidisciplinary team - urologic oncology, radiology, pathology, radiation oncology, and rehabilitation - reviewed his case together. Their consensus: intermediate-high risk localized prostate cancer with clear indication for robotic-assisted radical prostatectomy (RARP); treatment must balance oncological radicality (R0 resection) with functional preservation (urinary continence and erectile function); individualized nerve-vascular bundle (NVB) dynamic preservation strategy based on side-specific risk assessment.
His family brought him to Shanghai and sought care from Dr. Ye Dingwei, Chief of Urology at Fudan University Shanghai Cancer Center, through China Medical Concierge - Shanghai (CMCS).
Understanding Robotic Radical Prostatectomy: Why Precision and Individualization Change Functional Outcomes
- Robotic assistance transforms the precision of radical prostatectomy - the Da Vinci robotic system provides 10x magnified 3D visualization, tremor filtration, and 7-degree-of-freedom instrument articulation in the confined pelvic space; these capabilities allow the surgeon to identify and develop the fine anatomical planes - between the prostate capsule, the neurovascular bundles, the urethral sphincter, and the bladder neck - with a precision that is not achievable through open or standard laparoscopic approaches; the result is higher rates of R0 resection, better functional preservation, and lower blood loss
- Individualized nerve-sparing strategy based on side-specific risk is the oncological and functional standard - the neurovascular bundles that control erectile function run along the posterolateral surface of the prostate; preserving them reduces the risk of erectile dysfunction but carries a risk of positive surgical margins if the tumor has extended beyond the capsule on that side; the correct strategy is not uniform nerve-sparing or uniform wide excision - it is individualized assessment of extracapsular extension risk on each side, with nerve-sparing on the low-risk side and wide excision on the high-risk side; this asymmetric approach maximizes both oncological safety and functional preservation
- Athermal nerve-sparing technique minimizes thermal injury to the neurovascular bundle - conventional energy devices (bipolar, ultrasonic) generate heat that diffuses to adjacent tissue, causing thermal neuropraxia of the neurovascular bundle even when the bundle is anatomically preserved; athermal technique - using Hem-o-lok clips for hemostasis instead of energy devices - eliminates this thermal injury, preserving the functional integrity of the nerve fibers and accelerating the return of erectile function after nerve-sparing prostatectomy
- Bladder neck preservation and Rocco reconstruction optimize early continence recovery - preservation of the circular smooth muscle of the bladder neck maintains the proximal urinary sphincter mechanism, reducing the dependence on the external sphincter alone for continence; the Rocco posterior reconstruction - reapproximating the puboprostatic ligaments and levator ani complex before the urethrovesical anastomosis - restores the posterior support of the sphincter complex, significantly improving early continence rates in the first weeks after catheter removal
- Extended pelvic lymph node dissection provides accurate staging and potential therapeutic benefit - standard pelvic lymph node dissection misses up to 50% of positive nodes in intermediate-high risk prostate cancer; extended PLND - covering the obturator, external iliac, internal iliac, and presacral regions - provides accurate nodal staging that guides adjuvant therapy decisions and may offer a therapeutic benefit through removal of micrometastatic disease; the minimum quality threshold for meaningful staging is retrieval of at least 10 nodes
- PSMA PET/CT is the most sensitive staging tool for intermediate-high risk prostate cancer - conventional CT and bone scan miss a significant proportion of pelvic lymph node and distant metastases in intermediate-high risk prostate cancer; 68Ga-PSMA PET/CT, which targets the prostate-specific membrane antigen expressed on prostate cancer cells, detects nodal and distant metastases with significantly higher sensitivity and specificity, preventing unnecessary radical surgery in patients with occult metastatic disease and ensuring that surgical candidates are truly localized
About Dr. Ye Dingwei
Dr. Ye Dingwei is the Chief of Urology at Fudan University Shanghai Cancer Center (FUSCC) - China's premier cancer center. China's foremost urologic oncologist, Dr. Ye specializes in robotic-assisted radical prostatectomy and bladder cancer surgery, and has led multiple national multicenter trials in urological malignancies. His practice integrates mpMRI-PSMA PET fusion planning, individualized NVB preservation strategy, athermal dissection technique, and structured functional rehabilitation to deliver oncological and functional outcomes that benchmark against the world's leading robotic prostatectomy programs.
His clinical expertise spans:
- Robotic-assisted radical prostatectomy (RARP) - Da Vinci Xi RARP for localized and locally advanced prostate cancer, with individualized nerve-sparing strategy based on mpMRI and PSMA PET risk assessment; bladder neck preservation, Rocco reconstruction, and athermal NVB dissection as standard technique; extended pelvic lymph node dissection for intermediate-high and high-risk disease
- Robotic radical cystectomy and urinary diversion - robotic radical cystectomy with intracorporeal ileal conduit and neobladder reconstruction for muscle-invasive bladder cancer; enhanced recovery protocols and structured functional rehabilitation
- Kidney cancer surgery - robotic partial nephrectomy for renal cell carcinoma, with zero-ischemia and selective arterial clamping techniques for nephron preservation; robotic radical nephrectomy with inferior vena cava thrombectomy for advanced renal tumors
- Urological oncology multidisciplinary management - leadership of FUSCC's urological oncology MDT, integrating urology, medical oncology, radiation oncology, radiology, and pathology in coordinated treatment planning for prostate, bladder, kidney, and upper tract urothelial cancers
- National multicenter trial leadership - principal investigator of national multicenter trials in prostate and bladder cancer; contributor to China's national urological oncology guidelines; international collaboration with leading urological oncology research groups
The Case That Showed What Precision Robotic Prostatectomy Delivers
The Situation
A 62-year-old associate professor. PSA rising from 4.2 to 11.8 ng/mL over 18 months. PI-RADS 5 right peripheral zone lesion 3.1 cm with suspected ECE. Gleason 4+3=7 (Grade Group 3) right side, Gleason 3+3=6 left side. PSMA PET/CT negative for nodal or distant metastases. cT2cN0M0 intermediate-high risk. ECOG PS 0. A patient whose career depended on urinary control and whose quality of life depended on functional preservation. MDT consensus: Da Vinci Xi RARP with ePLND and individualized NVB strategy - wide excision right, athermal nerve-sparing left. One question: is there a urologic oncologist with the robotic prostatectomy volume, the individualized nerve-sparing expertise, and the functional rehabilitation infrastructure to achieve R0 resection while giving this patient his continence and his dignity back?
The Assessment and Procedure
Dr. Ye reviewed Mr. Zhang's mpMRI and PSMA PET fusion reconstruction. AI-assisted annotation identified the suspected ECE zone on the right, the NVB trajectory bilaterally, and the pelvic floor muscle attachments. The predictive model estimated right-sided capsular invasion probability at 68% and left-sided at less than 25% - confirming the asymmetric strategy: non-nerve-sparing wide excision on the right, athermal interfascial NVB preservation on the left.
"On the right side, where the tumor is most likely to have grown through the capsule, we will take a wide margin - no nerve preservation on that side. On the left side, where the risk is low, we will use a technique that avoids any heat near the nerve bundle, because heat is what damages the nerves even when you think you are preserving them. We will check the left-sided margin with frozen section during the operation. If it is clear, we confirm the nerve preservation. If it is not, we widen the excision. The goal is R0 - clean margins - on both sides. The function follows from that."
Surgery was performed transperitoneally with the Da Vinci Xi system. Early bladder neck transection preserved the circular smooth muscle ring. The vas deferens was ligated high to prevent tumor cell dissemination.
On the right side: wide extrafascial excision with non-nerve-sparing resection to ensure clear margins in the suspected ECE zone. On the left side: athermal interfascial NVB preservation along the lateral Denonvilliers fascia plane using Hem-o-lok clips exclusively - no energy devices. Intraoperative frozen section of the left basal margin confirmed negative - nerve preservation confirmed.
Extended PLND covered the obturator, external iliac, internal iliac, and presacral regions - 18 nodes retrieved, all reactive on intraoperative assessment, no micrometastases.
Urethrovesical anastomosis was completed with continuous V-Loc barbed suture. Rocco posterior reconstruction reapproximated the puboprostatic ligaments and levator ani complex before anastomosis, restoring posterior sphincter support.
Total operative time: 108 minutes. Blood loss: 75 mL. No transfusion.
The Recovery
Ambulation on day 1. Cystogram on day 7 confirmed no anastomotic leak - catheter removed. Pelvic floor biofeedback training and core stability rehabilitation initiated.
Final pathology: pT2cN0, Gleason 4+3=7, R0 resection, perineural invasion positive, surgical margins negative. 0 of 18 lymph nodes positive.
At 1 month: daytime continence rate 85%. At 3 months: fully continent without pads, 24 hours - ICIQ-SF score 0. On-demand tadalafil 5 mg initiated for erectile rehabilitation.
At 6 weeks: PSA below 0.01 ng/mL - biochemical remission confirmed. PSA remained at the limit of detection at every 3-monthly check through 12 months. MRI at 12 months: no local recurrence. PSMA PET: negative. No adjuvant hormone therapy or radiotherapy initiated.
At 12 months: IIEF-5 score 18 - moderate erectile function recovery, sufficient for light sexual activity. Mr. Zhang had returned to the lectern and the gym. He sent a message to CMCS: "From 'worried the cancer won't be fully removed' to 'back at the lectern and in the gym' - robotic surgery gave me precision and dignity back. I did not have to choose between being cured and being myself."
Outcome Summary
- ✅ R0 resection confirmed - pT2cN0, Gleason 4+3=7, surgical margins negative bilaterally; 0/18 lymph nodes positive; perineural invasion present but margins clear
- ✅ PSA below 0.01 ng/mL from 6 weeks, sustained at 12 months - biochemical remission confirmed; no adjuvant hormone therapy or radiotherapy required; PSMA PET negative at 12 months
- ✅ Full continence without pads at 3 months - ICIQ-SF 0 at 3 months; daytime continence 85% at 1 month; Rocco reconstruction and bladder neck preservation contributed to early recovery
- ✅ Moderate erectile function recovery at 12 months - IIEF-5 18 at 12 months with on-demand tadalafil; left-side athermal NVB preservation enabled functional recovery on the preserved side
- ✅ Individualized nerve-sparing strategy confirmed safe - intraoperative frozen section of left basal margin negative before confirming nerve preservation; right-side wide excision ensured oncological safety at the high-risk ECE site
- ✅ Returned to lectern and gym at 3 months - professional and recreational function fully restored; quality of life preserved alongside oncological cure
- ✅ World-class outcome at a fraction of the cost - Da Vinci Xi RARP with ePLND, athermal NVB preservation, Rocco reconstruction, and structured functional rehabilitation in Shanghai at a fraction of US or European costs
"He was 62. Intermediate-high risk prostate cancer with suspected extracapsular extension on the right. A professor whose career depended on urinary control. Dr. Ye Dingwei at Fudan University Shanghai Cancer Center performed Da Vinci Xi RARP with wide excision on the high-risk side and athermal nerve-sparing on the low-risk side - R0 confirmed, 18 nodes retrieved, all negative. At 3 months, PSA was undetectable and Mr. Zhang was continent without pads. At 12 months, he was back at the lectern and in the gym."
Why Shanghai for Robotic Prostate Cancer Surgery?
- World-class outcomes at a fraction of the cost - Da Vinci Xi RARP with mpMRI-PSMA PET fusion planning, individualized NVB strategy, athermal dissection, Rocco reconstruction, and ePLND in Shanghai at a fraction of US or European costs
- China's foremost urologic oncologist leading the program - Dr. Ye Dingwei's national multicenter trial leadership, guideline contributions, and FUSCC institutional infrastructure place his robotic prostatectomy program among the most experienced and evidence-aligned in Asia
- Individualized nerve-sparing as standard, not exception - side-specific NVB risk assessment based on mpMRI and PSMA PET, with athermal preservation technique on the low-risk side, is the standard approach for every eligible patient in Dr. Ye's program - not a premium option reserved for selected cases
- Integrated functional rehabilitation from day 7 - pelvic floor biofeedback, core stability training, and PDE5i erectile rehabilitation are structured components of the post-prostatectomy pathway, not afterthoughts; the functional outcomes that matter to patients are built into the program from the day the catheter is removed
How CMCS Supports International Patients Seeking Prostate Cancer Surgery in Shanghai
- 🏥 Specialist access - direct connection to Dr. Ye Dingwei and Fudan University Shanghai Cancer Center's Department of Urology
- 📋 PSA results, mpMRI, PSMA PET/CT, biopsy pathology, and prior treatment records translation and coordination
- 🗣️ On-site medical interpretation at every consultation, procedure, and follow-up
- ✈️ Travel and logistics coordination - visa, accommodation, airport transfers
- 📞 24/7 concierge support from first inquiry through every stage of treatment
- 🔄 Post-treatment follow-up - PSA surveillance coordination, functional rehabilitation support, imaging follow-up scheduling, and long-term urological oncology management support
📢 Subscribe to China Medical Concierge - Shanghai (CMCS)
We're delighted to offer you trusted medical tourism and personalized medical concierge services, giving you and your loved ones an extra pathway to quality care from China.
💬 Got questions? Drop a comment or DM us - we're always here to help!
📢 Have your own incredible medical story in China? Share it with us in the comments below!
#ChinaMedicalTour #AffordableHealthcare #MedicalTourismChina #ChinaHealthcare #MedicalConcierge #ProstateCancer #RoboticSurgery #RARP #YeDingwei #FudanCancerCenter
🤝 Connect With CMCS
Struggling with long medical waitlists? Facing barriers to overseas treatment? China Medical Concierge - Shanghai (CMCS) helps international patients access premium medical care in Shanghai's top public and private hospitals, with end-to-end personalized support.
Contact us for international patient support:
📧 contract@medicalsh.com | 🌐 medicalsh.com
0 Kommentare